SCHEMBL2473276

SCHEMBL2473276

CN1CCN(CCN(Cc2ccc(C(=O)Nc3ccccc3N)cc2)C(=O)Nc2cccc(F)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 10/20 0.50
ALDH1A1 P00352 3/20 0.48
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
THRB P10828 1/20 0.45
MAPK1 P28482 1/20 0.45
HDAC3 O15379 3/20 0.45
HDAC8 Q9BY41 2/20 0.45
BTK Q06187 1/20 0.45
HDAC2 Q92769 3/20 0.45
NCOR2 Q9Y618 1/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 1/20 0.45
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474554 0.91 KDM1A (0.47) HDAC1ALDH1A1LMNAGAATHRB
SCHEMBL3835983 0.89 HDAC1 (0.46) HDAC1ALDH1A1LMNAGAATHRB
SCHEMBL2384663 0.89 ALDH1A1 (0.45) HDAC1ALDH1A1LMNAGAATHRB
SCHEMBL2476097 0.87 UBE2M (0.51) HDAC1ALDH1A1HDAC3HDAC8HDAC2
SCHEMBL3835064 0.87 KDM1A (0.45) HDAC1ALDH1A1LMNAGAATHRB
SCHEMBL2498331 0.86 KDM1A (0.49) HDAC1LMNAHDAC3HDAC8HDAC2
SCHEMBL2480569 0.86 EGFR (0.47) HDAC1ALDH1A1GAAMAPK1HDAC3
SCHEMBL2471515 0.85 HDAC1 (0.51) HDAC1ALDH1A1GAAHDAC3HDAC8
SCHEMBL3830885 0.85 HDAC1 (0.60) HDAC1ALDH1A1LMNAMAPK1HDAC3
SCHEMBL2474439 0.85 HDAC1 (0.53) HDAC1ALDH1A1LMNAGAATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885ALDH1A1 1040/4885LMNA 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.